Abivax shares rise as investors revisit recent ECCO updates ahead of 2026 trial milestones

Abivax S.A. (ABVX) is up 3.7% today. Here is some analysis on what might have caused this price movement.

Analysis: ABVX appears to be moving higher on continued investor digestion of recently released inflammatory bowel disease updates around obefazimod, with attention shifting to upcoming 2026 clinical milestones. With no obvious, same-day company announcement, the move may also reflect positioning into the next scheduled corporate update and broader biotech risk-on sentiment.

Details:

In late February 2026, the company highlighted new preclinical anti-fibrotic evidence for obefazimod alongside additional clinical efficacy, safety, and biomarker analyses presented at the ECCO 2026 meeting.

Earlier company materials outlined expectations for Phase 3 ABTECT-UC maintenance topline results by the end of Q2 2026, with a potential U.S. regulatory filing targeted for late 2026 (timing dependent on results).

ABVX also has a fiscal-year 2025 financial results date on the calendar later this month, which can drive incremental trading activity as investors position ahead of updates.

This could also be a technical rebound after recent volatility, as biotech names often trade sharply around conference read-throughs and upcoming catalysts.

Sources:

GlobeNewswire, Euronext, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ABVX Hedge Fund Activity

We have seen 175 institutional investors add shares of $ABVX stock to their portfolio, and 77 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DEEP TRACK CAPITAL, LP removed 3,480,144 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $295,464,225
MORGAN STANLEY added 1,681,277 shares (+114.3%) to their portfolio in Q4 2025, for an estimated $226,728,609
WESTFIELD CAPITAL MANAGEMENT CO LP added 1,009,966 shares (+inf%) to their portfolio in Q4 2025, for an estimated $136,198,964
ADAGE CAPITAL PARTNERS GP, L.L.C. added 977,629 shares (+inf%) to their portfolio in Q3 2025, for an estimated $83,000,702
VESTAL POINT CAPITAL, LP added 900,000 shares (+90.0%) to their portfolio in Q4 2025, for an estimated $121,369,499
DEUTSCHE BANK AG\ added 764,899 shares (+inf%) to their portfolio in Q4 2025, for an estimated $103,150,454
SUSQUEHANNA INTERNATIONAL GROUP, LLP added 720,222 shares (+2080.7%) to their portfolio in Q4 2025, for an estimated $97,125,537

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ABVX Analyst Ratings

Wall Street analysts have issued reports on $ABVX in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/25/2026
Citizens issued a "Market Outperform" rating on 12/16/2025
Truist Securities issued a "Buy" rating on 11/24/2025
Wolfe Research issued a "Outperform" rating on 11/06/2025
Barclays issued a "Overweight" rating on 10/13/2025
Guggenheim issued a "Buy" rating on 10/10/2025
JMP Securities issued a "Market Outperform" rating on 09/25/2025

To track analyst ratings and price targets for $ABVX, check out Quiver Quantitative's $ABVX forecast page.

$ABVX Price Targets

Multiple analysts have issued price targets for $ABVX recently. We have seen 9 analysts offer price targets for $ABVX in the last 6 months, with a median target of $142.0.

Here are some recent targets:

Julian Harrison from BTIG set a target price of $150.0 on 02/25/2026
David Nierengarten from Wedbush set a target price of $110.0 on 02/24/2026
Judah Frommer from Morgan Stanley set a target price of $145.0 on 01/09/2026
Jason Butler from Citizens set a target price of $131.0 on 12/16/2025
Gregory Renza from Truist Securities set a target price of $140.0 on 11/24/2025
Steve Fleishman from Wolfe Research set a target price of $176.0 on 11/06/2025
Etzer Darout from Barclays set a target price of $142.0 on 10/13/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.